

GLAUCOMA PIPELINE 2026 PHARMACEUTICAL


A VIEW INTO ONGOING INNOVATION

Content guidance and source: Deborah Ristvedt, DO, and Manjool Shah, MD
*Editorially independent content supported by advertising from Glaukos

LEGEND

Approved drugs or drug classes

Novel/investigational therapy approaches



- ★ Alpha-Agonists
- ▲ ATP Potassium Channel Openers
- ▲● Autotaxin-Lysophosphatidic Acid
- Beta-Blockers
- Carbonic Anhydrase Inhibitors
- ★ Muscarinic Agonists (Miotics)
- ▲●★ NCX 470 (Nicox)
- ▲●★ Nitric Oxide-Donating Compounds
- ★ Omlonti (Omidenepag isopropyl; Ocuvox)
- ▲●★ Prostaglandin Analogues
- QLS-111 (Qlaris Bio)
- ▲● Rho Kinase Inhibitors

COMBINATION MEDICATIONS

(Advantages ↑ compliance, adherence ↓ preservative, copy)

- ★ **Combigan** (Brimonidine Tartrate & Timolol Maleate; AbbVie)
- **Cosopt / Cosopt PF** (Dorzolamide HCl & Timolol Maleate; Thea Pharma)
- ▲●★ **Rocklatan** (Netarsudil & Latanoprost; Alcon)
- ★ **Simbrinza** (Brinzolamide & Brimonidine tartrate; Alcon)

SUSTAINED RELEASE TECHNOLOGIES

Approved
Durysta (Bimatoprost SR; AbbVie)
iDose TR Procedural pharmaceutical (Travoprost; Glaukos)

Under Investigation
AGN-193408 (AbbVie)
ENV515 Intraocular Implant (Envisia Therapeutics)
Evolvate Punctal Plug (Mati Therapeutics)
GLK-311 Transdermal sustained-release platform (Glaukos)
iDose TREX (Glaukos)
PA5108 Latanoprost biodegradable implant (PolyActiva)
OTX-TIC Bioresorbable Travoprost Intracameral Implant (Ocular Therapeutix)
SpyGlass Drug Delivery System Drug-delivering IOL (SpyGlass Pharma)

Emerging Technologies

Contact Lens Drug Delivery
Includes micelles-loaded contact lenses; chitosan-based nano-coating; diamond nano-gel embedded lenses; lenses with embedded microtubes; temperature sensitive lenses

Nanotechnology

Includes polymeric hydrogels (microspheres, dendrimer nanofiber); microemulsions; nanosuspensions; nanoemulsions; nano-pharmaceuticals (nanoparticles); vesicular delivery systems / nanovesicles (liposomes, cubosomes, cationic phospholipids, non-ionic surfactants); *in situ* assembly systems; emulsomes; gold nanoparticles
• Examples: **Catiolanze** Latanoprost-loaded nanoemulsion (Santen)

Indications And Usage
iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

View full Prescribing Information at [idosetrhcp.com](https://www.idosetrhcp.com)

IMPORTANT SAFETY INFORMATION
Dosage And Administration
For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications
iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings And Precautions
iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions
In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperemia, and reduced visual acuity. Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

References: 1. Sarkisian SR et al. *Ophthalmol Ther.* 2024;13(4):995-1014. 2. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023. 3. Bacharach J et al. *Glaucoma Today.* 2020;40:43. 4. Berdahl JP et al. *Drugs.* 2024;84(1):83-97.
©2025 Glaukos Corporation. All rights reserved.
Glaukos and iDose are registered trademarks of Glaukos Corporation. PM-US-2920

★ **UVEOSCLERAL OUTFLOW**

▲ **AQUEOUS OUTFLOW: THE CANAL AND BEYOND**

● **AQUEOUS OUTFLOW AT MESHWORK**

■ **AQUEOUS PRODUCTION**

If you would like to submit an addition for next year's poster, please email Cara Deming at cdeming@bmctoday.com.

View Interactive Version Online




CRST Cataract & Refractive Surgery Today
GT Glaucoma Today
MODERNOPTOMETRY

Drowning from the burdens of drops?

Rise above the flood.
With iDose TR, 8 of 10 patients were completely free of prescription eye drops at 12 months.¹

- iDose TR is a game-changing procedural pharmaceutical that enables earlier intervention^{2,3}
- Designed to deliver up to 3 years of continuous IOP control⁴
- Helps reduce many of the burdens of drops—compliance issues, possible disease progression, and administrative headaches⁴
- Introduces your patients to interventional glaucoma without the need for drops¹



SEEK AN ALTERNATIVE OPTION

iDose TR (travoprost intracameral implant) 75 mcg

Actual size of implant: 1.8 mm x 0.5 mm


GLAUCOMA PIPELINE

A VIEW INTO ONGOING INNOVATION

2026 SURGICAL

LEGEND
■ Implant
■ Surgical Device/
Instrument
■ Laser

OUS: Outside of the United States



SUBCONJUNCTIVAL OUTFLOW

MINIMALLY INVASIVE BLEB SURGERIES

- **Minimally Invasive Micro Sclerostomy** (MIMS, Sanoculis) Investigational
- **PreserFlo MicroShunt** (Santen/Glaukos) – external Approved OUS
- **VisiPlate** (Avisi Technologies) Investigational
- **XEN45 Gel Stent** (AbbVie) – internal/external
- **XEN63 Gel Stent** (AbbVie) Investigational Approved OUS

INCISIONAL SURGERIES

- **AquaLumen** (PLU Ophthalmic)
- Aqueous Drainage Devices
 - **Ahmed Glaucoma Valve** (New World Medical)
 - **Ahmed ClearPath** (New World Medical)
 - **BAERVELDT Glaucoma Implant** (Johnson & Johnson Vision)
 - **Calibreye** (Myra Vision) Investigational
 - **CorNeat eShunt** (CorNeat Vision) Investigational
 - **eyeWatch** (Rheon Medical) Investigational
 - **Gore Glaucoma Drainage Implant** (WL Gore & Associates) Investigational
 - **Molteno3** (Nova Eye Medical)
 - **PAUL Implant** (Advanced Ophthalmic Innovations) Investigational
- Trabeculectomy

UVEOSCLERAL OUTFLOW

- **AlloFlo** (Iantrek)
- **Cilio-Scleral Inter-Positioning Device** (Ciliotech) Investigational
- **MINject** (iSTAR Medical) Approved OUS

CONVENTIONAL OUTFLOW {Mechanisms of action: ■ Stenting ★ Cutting ● Dilating}

- ★ **Bent Ab Interno Needle Goniectomy**
- ★ **C-Rex** (Iantrek)
- ★ **Elios Vision System** (Bausch + Lomb) Approved OUS
- **eyeFlow Microstent System** (eyeFlow) Investigational
- ★ **Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLIGHT)** (ViaLase) Approved OUS
- ★ **Gonioscopy-Assisted Transluminal Trabeculotomy**
- ■ **Hydrus Microstent** (Alcon)
- ★ **iAccess** (Glaukos)
- **iStent infinite** (Glaukos)
- **iStent inject W** (Glaukos)
- **iTrack Advance** (Nova Eye Medical)
- ★ **KDB GLIDE** (New World Medical)
- ★ **Laser Trabeculoplasty** (laser wavelength)
 - **Argon Laser** (488/514 nm [Argon Laser] or 532 nm [Nd:YAG])
 - **Selective Laser** (532 nm)
 - **MicroPulse Laser Trabeculoplasty** (810 nm – Iridex)
 - **Voyager DSLT** (Alcon)
- ★ **Minimally Invasive Nasal Trabeculostomy** (MINT, Sanoculis) Approved OUS
- ★ ● **OMNI Surgical System** (Sight Sciences)
- ★ **SION** (Sight Sciences)
- ★ ● **Streamline Surgical System** (New World Medical)
- ★ **Trabectome** (MicroSurgical Technology)
- ★ **TrabEx** (MicroSurgical Technology)
- ★ ● **VIA360** (New World Medical)

AQUEOUS INFLOW

- **Endoscopic Cyclophotocoagulation** (ECP, BVI Medical)
- **High-Intensity Focused Ultrasound** (HIFU - EyeOP1, Eye Tech Care) Investigational
- **Micropulse Diode Laser Transscleral Cyclophotocoagulation** (MP-TSCPC, Iridex)
- **Transscleral Cyclophotocoagulation** (TSCPC, Iridex)



DEBORAH RISTVEDT, DO

- Ophthalmologist, Vance Thompson Vision, Alexandria, Minnesota
- Deborah.ristvedt@vancethompsonvision.com
- Financial disclosures: Lecture fees (AbbVie, Glaukos, Sight Sciences)



MANJOOL SHAH, MD

- Clinical Assistant Professor, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan
- Member, GT Editorial Advisory Board
- manjool@med.umich.edu
- Financial disclosure: Consultant (Alcon, Glaukos)

CRST
Cataract & Refractive Surgery Today

GT
Glaucoma Today

MODERNOPTOMETRY

iStent infinite

The Beginning of the
Interventional Glaucoma Revolution
Infinite Possibilities



GLAUKOS